Novo Nordisk A/S
SOLID GLP-1 DERIVATIVE COMPOSITIONS FOR ORAL ADMINISTRATION
Last updated:
Abstract:
The present invention relates to solid compositions for oral administration comprising (i) a GLP-1 derivative and the SGLT2 inhibitor dapagliflozin or (ii) a GLP-1 derivative and a salt of NAC in combination with an SGLT2 inhibitor.
Status:
Application
Type:
Utility
Filling date:
8 Oct 2021
Issue date:
20 Jan 2022